Association of vitamin D and platelet-to-lymphocyte ratio in treatment escalation risk for newly diagnosed Crohn’s disease adults

Table 3 Interaction between platelet-to-lymphocyte ratio and baseline VD deficiency on Infliximab and/or immunosuppressants usage in newly diagnosed CD patients

VD deficiency	n	person- months	Events	Crude model		Adjusted model*
VD deficiency	n	person- months	(%)	HR (95% CI)	P	HR (95% CI)	P
Platelet-to-lymphocyte ratio < Q1
No	4	10	1 (25.0)	Ref	—	Ref	—
Yes	18	100	5 (27.8)	1.20 (0.13–10.79)	0.871	ns	ns
Platelet-to-lymphocyte ratio ≥ Q1
No	19	78	7 (36.8)	Ref	—	Ref	—
Yes	67	292	41 (61.2)	1.64 (0.73–3.65)	0.230	4.17 (1.51–11.53)	0.006
				P^a_interaction = 0.943		P^a_interaction = 0.031

*Adjusted for age of onset, sex, region, smoking, season of vitamin D measurement, disease location, disease behavior, occupation, BMI, CDAI, EIM and history of perianal surgery
^aP value of the interaction between platelet-to-lymphocyte ratio and VD deficiency
ns: non-significant

ISSN: 1475-2891